Drug Profile

Irinotecan sucrosofate companion diagnostic - Merrimack Pharmaceuticals

Alternative Names: Ferumoxytol - Merrimack Pharmaceuticals; MM-398 companion diagnostic

Latest Information Update: 11 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Merrimack Pharmaceuticals
Class Antianaemics; Contrast media; Diagnostic agents; Ferric compounds; Ferrous compounds; Heavy metals; Minerals; Vascular disorder therapies
Mechanism of Action Magnetic resonance imaging enhancers

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Solid tumours

Most Recent Events

20 May 2024 Discontinued - Phase-I for Solid tumours (Diagnosis) in USA (IV)
16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Diagnosis) in USA (IV, Infusion)
08 Apr 2014 Preliminary efficacy and adverse events data from a phase I pilot study released by Merrimack Pharmaceuticals

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com